Search results
Results from the WOW.Com Content Network
A well studied model is celiac disease, in which increased intestinal permeability appears secondary to the abnormal immune reaction induced by gluten and allows fragments of gliadin protein to get past the intestinal epithelium, triggering an immune response at the intestinal submucosa level that leads to diverse gastrointestinal or extra ...
Intestinal permeability is a measurement of intestinal mucosal barrier function and is defined as "the facility with which intestinal epithelium allows molecules to pass through by non-mediated passive diffusion." [11] Permeability in this respect is mostly related to the measurable passage of ions and small inert molecules. Standard methods ...
The symptoms of bacterial overgrowth include nausea, flatus, [5] constipation, [6] bloating, abdominal distension, abdominal pain or discomfort, diarrhea, [7] fatigue, and weakness. SIBO also causes an increased permeability of the small intestine. [8] Some patients may lose weight.
Prokinetic medications are effective in treating functional dyspepsia by stimulating the contractions of the stomach's smooth muscle and have been suggested as initial treatments for PDS. Prokinetics include agonists of the 5-HT receptor 4 (5-HT4), antagonists of the D(2) dopamine receptor , and agonists of the motilin receptor , such ...
Leaky gut syndrome is a hypothetical and medically unrecognized condition [1] [2] that is distinct from the scientific phenomenon of increased intestinal permeability commonly known as "leaky gut". [ 1 ] [ 3 ] Claims for the existence of "leaky gut syndrome" as a distinct medical condition come mostly from nutritionists and practitioners of ...
First-pass metabolism may occur in the liver (for propranolol, lidocaine, clomethiazole, and nitroglycerin) or in the gut (for benzylpenicillin and insulin). [4] The four primary systems that affect the first pass effect of a drug are the enzymes of the gastrointestinal lumen, [5] gastrointestinal wall enzymes, [6] [7] [8] bacterial enzymes [5] and hepatic enzymes.
Prokinetics (medications focused on increasing gut motility), such as metoclopramide or erythromycin, has a history of use as a secondary treatment for dyspepsia. [6] While multiple studies show that it is more effective than placebo, there are multiple concerns about the side effects surrounding the long-term use of these medications.
The goal of treatment is toward achieving remission, after which the patient is usually switched to a lighter drug with fewer potential side effects. Every so often, an acute resurgence of the original symptoms may appear; this is known as a "flare-up". Depending on the circumstances, it may go away on its own or require medication.